The funding will support development for the company’s SB-1 Remedisc treatment, according to a March 28 news release. It is a seven-amino acid chain peptide and designed to decrease inflammation and maintain the structural integrity of the disc.
The funding was led by Viscogliosi Bros. Existing investors include Cercano Management and Pacira Biosciences.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
